Management of Osteonecrosis of the Jaws in Patients With History of Bisphosphonates Therapy
Nenhuma Miniatura disponível
Data
2010-11-01
Orientador
Coorientador
Pós-graduação
Curso de graduação
Título da Revista
ISSN da Revista
Título de Volume
Editor
Lippincott Williams & Wilkins
Tipo
Artigo
Direito de acesso
Acesso restrito
Resumo
Bisphosphonates are compounds used in the treatment of various metabolic and malignant bone diseases. The relation between the use of bisphosphonates and ostenonecrosis of the jaws as an adverse effect of the drug has been intensely discussed during the last few years, and up to this moment, there is no consensus concerning an ideal treatment modality for this condition. Nevertheless, there is an agreement among researchers that the standard goal for controlling jaw osteonecrosis is to prevent it. Otherwise, the rationale for a randomized controlled trial is that current treatment has proven to be suboptimal, and no consensus has been reached yet on the best strategies to repair the exposed bone once bone necrosis is developed. This article is focused on reporting a case of moderate osteonecrosis of the upper jaw induced by bisphosphonates and discusses a possible role for surgical debridement associated to platelet-rich plasma, hyperbaric oxygen therapy, and the cessation of the bisphosphonate use in managing this type of lesion. Moreover, the dentist, the oral surgeon, and the oncologist need to work together to reach better outcomes.
Descrição
Palavras-chave
Idioma
Inglês
Como citar
Journal of Craniofacial Surgery. Philadelphia: Lippincott Williams & Wilkins, v. 21, n. 6, p. 1962-1966, 2010.
